Emcure Pharmaceuticals Limited (BOM:544210)

Splunk Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	81,814	78,960	66,583	59,858	58,554	50,335
Revenue Growth (YoY)	18.28%	18.59%	11.23%	2.23%	16.33%	-0.30%
Cost of Revenue	33,414	32,225	25,357	23,185	22,864	19,269
Gross Profit	48,400	46,735	41,225	36,673	35,690	31,065
Selling, General & Admin	17,694	17,264	15,577	13,069	11,805	10,272
Other Operating Expenses	15,341	14,782	13,351	11,597	10,562	8,606
Operating Expenses	36,935	35,887	32,052	27,459	24,835	21,402
Operating Income	11,464	10,847	9,173	9,214	10,855	9,663
Interest Expense	-981.65	-1,302	-2,032	-1,849	-1,470	-1,140
Interest & Investment Income	90.44	90.44	207.59	118.34	101.97	69.87
Currency Exchange Gain (Loss)	562.84	437.59	203.77	190.15	367.78	30.33
Other Non Operating Income (Expenses)	-508.23	-314.36	-205.93	-137.55	-124.92	-66.8
EBT Excluding Unusual Items	10,628	9,759	7,346	7,536	9,730	8,557
Gain (Loss) on Sale of Investments	58.04	58.04	25.32	1.21	-	-
Gain (Loss) on Sale of Assets	-	-	-	-3.33	-4.08	4.29
Other Unusual Items	-138.78	-103.78	-99.31	-61.46	-	-153.82
Pretax Income	10,547	9,713	7,272	7,472	9,725	8,407
Income Tax Expense	2,850	2,639	1,997	1,854	2,700	2,334
Earnings From Continuing Operations	7,697	7,075	5,276	5,618	7,026	6,073
Earnings From Discontinued Operations	-	-	-	-	-	-1,887
Net Income to Company	7,697	7,075	5,276	5,618	7,026	4,186
Minority Interest in Earnings	-254.66	-261.35	-293.92	-298.26	-403.56	-264.47
Net Income	7,442	6,813	4,982	5,320	6,622	3,921
Net Income to Common	7,442	6,813	4,982	5,320	6,622	3,921
Net Income Growth	45.39%	36.76%	-6.36%	-19.66%	68.86%	369.04%
Shares Outstanding (Basic)	189	187	181	181	181	181
Shares Outstanding (Diluted)	189	187	181	181	181	181
Shares Change (YoY)	4.50%	3.41%	0.01%	-	-	-
EPS (Basic)	39.35	36.43	27.54	29.42	36.62	21.68
EPS (Diluted)	39.35	36.43	27.54	29.42	36.62	21.68
EPS Growth	39.15%	32.27%	-6.38%	-19.66%	68.90%	369.23%
Free Cash Flow	-	6,299	8,215	3,563	3,900	5,790
Free Cash Flow Per Share	-	33.68	45.42	19.70	21.57	32.02
Dividend Per Share	-	3.000	-	2.000	3.000	1.000
Dividend Growth	-	-	-	-33.33%	200.00%	-60.00%
Gross Margin	59.16%	59.19%	61.92%	61.27%	60.95%	61.72%
Operating Margin	14.01%	13.74%	13.78%	15.39%	18.54%	19.20%
Profit Margin	9.10%	8.63%	7.48%	8.89%	11.31%	7.79%
Free Cash Flow Margin	-	7.98%	12.34%	5.95%	6.66%	11.50%
EBITDA	14,899	14,121	11,805	11,446	12,911	12,419
EBITDA Margin	18.21%	17.88%	17.73%	19.12%	22.05%	24.67%
D&A For EBITDA	3,434	3,274	2,632	2,232	2,057	2,756
EBIT	11,464	10,847	9,173	9,214	10,855	9,663
EBIT Margin	14.01%	13.74%	13.78%	15.39%	18.54%	19.20%
Effective Tax Rate	27.02%	27.17%	27.45%	24.81%	27.76%	27.77%
Revenue as Reported	82,293	79,633	67,021	60,317	59,189	50,674
Advertising Expenses	-	2,734	2,585	1,828	1,633	1,220

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.